-
Founded in:
2015-01-23 -
Country:
China -
Address:
No. 22, Yangheng 4th Road, Yang'an Industrial Park, Qionglai City -
Tax NO.:
91510183327478671X -
Registered Funds:
20 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| iron succinate |
Iron is one of the important elements of the human body. It participates in the composition of hemoglobin and plays an important role in transferring oxygen and participating in human metabolic activities. Iron is the main component of hemoglobin and myoglobin. Hemoglobin is the main carrier of oxygen in red blood cells. Myoglobin is the site where muscle cells store oxygen and provides oxygen for muscle movement. Most enzymes and factors related to the tricarboxylic acid cycle contain iron, or can only function in the presence of iron. After actively supplementing iron for iron-deficient patients, in addition to accelerating hemoglobin synthesis, symptoms related to tissue iron deficiency and reduced iron-containing enzyme activity, such as growth retardation, abnormal behavior, lack of physical strength, changes in mucous tissues, and skin and nail lesions can also be gradually corrected.
More
Iron is one of the important elements of the human body. It participates in the composition of hemoglobin and plays an important role in transferring oxygen and participating in human metabolic activities. Iron is the main component of hemoglobin and myoglobin. Hemoglobin is the main carrier of oxygen in red blood cells. Myoglobin is the site where muscle cells store oxygen and provides oxygen for muscle movement. Most enzymes and factors related to the tricarboxylic acid cycle contain iron, or can only function in the presence of iron. After actively supplementing iron for iron-deficient patients, in addition to accelerating hemoglobin synthesis, symptoms related to tissue iron deficiency and reduced iron-containing enzyme activity, such as growth retardation, abnormal behavior, lack of physical strength, changes in mucous tissues, and skin and nail lesions can also be gradually corrected. |
34.0%~36.0%Anhydrous basic salt | 10030-90-7 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| iron succinate |
Not clearly described
More
Not clearly described |
10030-90-7 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sertraline hydrochloride |
Extract from the above information
More
Extract from the above information |
79559-97-0 | 52 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Midodrine hydrochloride |
The original form of this product is inactive. It is converted into the active metabolite desglymidodrine after aminoacetyl hydrolysis. Desglymidodrine is a selective peripheral sympathetic a1 receptor agonist, which acts directly on the postsynapse to release adrenaline stimulants. It has the function of regulating vascular tension, which can increase peripheral arterial and venous resistance, prevent a large amount of blood from accumulating in the lower limbs, promote blood return, keep blood volume stable, increase upright blood pressure, and improve symptoms caused by insufficient circulation volume. It will not cause increased excitability of the central nervous system and has no direct effect on the heart, but the heart rate may decrease due to feedback after taking the drug.
More
The original form of this product is inactive. It is converted into the active metabolite desglymidodrine after aminoacetyl hydrolysis. Desglymidodrine is a selective peripheral sympathetic a1 receptor agonist, which acts directly on the postsynapse to release adrenaline stimulants. It has the function of regulating vascular tension, which can increase peripheral arterial and venous resistance, prevent a large amount of blood from accumulating in the lower limbs, promote blood return, keep blood volume stable, increase upright blood pressure, and improve symptoms caused by insufficient circulation volume. It will not cause increased excitability of the central nervous system and has no direct effect on the heart, but the heart rate may decrease due to feedback after taking the drug. |
3092-17-9 | 18 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cetirizine dihydrochloride |
Antihistamine effect
More
Antihistamine effect |
83881-52-1 | 54 |